Beacon Medicare Limited has launched Nivolunix in injection form under the generic of Nivolumab, for treating certain types of cancer. The product was prepared only for export purpose.
The medicine will be available in two strengths –40mg/4ml and 100mg/10ml –injections and a vial of the injection.
Nivolunix is a humanized antibody that is used in cancer immunotherapy that includes melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and Hepatocellular carcinoma (HCC) which is the most common type of primary liver cancer.
Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.
After the successful launching of the product at a function in Dhaka on January 22, 2020, high ups of the Beacon, the country’s one of the leading and fastest growing pharmaceutical companies, expected that the product will enrich the product of the company.
Apart from this, it will bring good sales from the international market to boost the national economy and will earn reputation for overall betterment of the company.